Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls

Biochemistry, Genetics and Molecular Biology

• Nested Gene 33%
• Tandem Mass Spectrometry 33%
• Agonist 33%
• Accuracy 33%
• Clinical Trial 33%
• Metabolic Pathway 16%
• Drug Screening 16%
• Urine Sampling 16%
• Upregulation 16%
• Electric Potential 16%
• Athletic Performance 16%
• Mass Spectrometry 16%
• Screening 16%
• Liquid Liquid Extraction 16%
• Enzymatic Hydrolysis 16%
• Synthesis 16%
• Electrospray Mass Spectrometry 16%
• Collision-Induced Dissociation 16%
• Peroxisome Proliferator-Activated Receptor Delta 16%
• Oxygenation 16%
• Lipoprotein 16%
• Aerobic Metabolism 16%
• Carbohydrate 16%
• Dyslipidemia 16%
• Sulfone 16%
• Nuclear Magnetic Resonance Spectroscopy 16%
• Regulatory Mechanism 16%
• Sample 16%
• Energy 16%
• Lipid 16%
• Liquid Chromatography 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Doping 100%
• GW501516 83%
• Rufloxacin 33%
• Electrospray Ionization 16%
• Drug 16%
• Carbohydrate 16%
• Metabolic Syndrome X 16%
• Lipid 16%
• Dyslipidemia 16%
• Agonist 16%
• Drug Screening 16%